Peskopihaja Injection 1200/600 mg (Pertuzumab/Trastuzumab)

Adult administration

This medication must be administered subcutaneously in the thigh and should not be given intravenously. The initial dose is 1200 mg of pertuzumab and 600 mg of trastuzumab administered over 8 minutes, followed by a 30-minute observation. The maintenance dose is 600 mg of pertuzumab and 600 mg of trastuzumab administered over 5 minutes every 3 weeks, followed by a 15-minute observation. Patients who have received the last intravenous dose of pertuzumab and trastuzumab less than 6 weeks prior should receive maintenance.

This medication may affect left ventricular function, so cardiac function tests must be performed prior to administration. During treatment, regular monitoring of cardiac function is necessary, and if abnormalities are found, administration may be discontinued. Symptoms such as allergic reactions related to infusion, fever, chills, and headache may occur during administration; medical staff should closely observe the patient for a certain period after administration. In case of severe infusion reactions, administration should be stopped immediately and appropriate treatment should be provided. This medication can reduce white blood cell counts, increasing the risk of infection; any signs of infection should be reported to medical personnel immediately. Severe allergic reactions such as hypersensitivity reactions or anaphylaxis can occur rarely, necessitating caution during administration. Patients with lung issues or difficulty breathing should avoid using this medication. If allergic to any ingredients in this medication, it should not be administered under any circumstances. Various side effects such as hair loss, fatigue, skin rash, muscle pain, diarrhea, vomiting, stomatitis, etc., can occur during administration, so the patient's condition should be closely monitored. Women who are pregnant or may become pregnant must use effective contraception during and for a certain period after administration, and this medication should not be used during pregnancy. Breastfeeding women should also avoid breastfeeding during the treatment period and for a certain time after treatment. The safety and efficacy of this medication in children under 18 years have not been established. While special dose adjustments are not required for elderly patients, they should be carefully monitored for the potential occurrence of side effects. There is insufficient safety information for patients with severely impaired kidney or liver function, so consultation with a specialist is necessary prior to use. This medication must be stored refrigerated and protected from light by maintaining its original packaging. Any remaining medication or waste should be disposed of in accordance with regulations to prevent environmental contamination.

Serious side effects

• Left ventricular dysfunction
• heart failure
• infusion-related reactions
• febrile neutropenia
• hypersensitivity/anaphylaxis
• pulmonary adverse reactions
• shortness of breath

Mild side effects

• Diarrhea
• injection site reactions
• asthenia
• fatigue
• rash
• dry skin
• muscle pain
• joint pain
• neutropenia
• anemia

This medication should be stored in a sealed container to prevent exposure to air and light, preferably at temperatures between 2 and 8 degrees Celsius. This will help maintain the medication’s effectiveness and prevent degradation.

Appearance

A colorless to pale yellow liquid filled in a colorless, transparent vial injectable solution

Package unit

1 vial/box [vial (15 mL)]